NeuroPace Inc — Form 8-K
Filed July 28, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 68/100
What the filing says
NeuroPace received FDA communication on July 28, 2026 stating its PMA Supplement for expanding RNS System into idiopathic generalized epilepsy (IGE) is not approvable in current form. FDA requested additional clinical evidence from the NAUTILUS trial and supporting literature. Company plans to submit a Submission Issue Request and continue collaborative dialogue with FDA; the NAUTILUS trial showed 77% median GTC seizure reduction at 18 months and 100% reduction in evaluable patients at 24 months.
Why this rating
IGE indication expansion is material to $306M company's growth strategy. Regulatory rejection delays revenue potential but interactive FDA engagement and strong trial data suggest resubmission pathway exists, reducing permanent deal-loss risk.
See more from July 28, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.